PR Newswire Asia's news > Medical/Pharmaceuticals

 < Previous page   |   Title only   |   Print    Next page > 
     
DA NANG GLOBAL BUSINESS SUMMIT 2026 - SILVER GENERATION INNOVATION EDITION
POSITIONING DA NANG AS SOUTHEAST ASIA'S INTERNATIONAL HUB FOR THE SILVER ECONOMY & MEDICAL TOURISM ...
2026-05-28T    Banking/Financial Service   Health Care/Hospital   Medical/Pharmaceuticals 
Asian Society of Cardiovascular Imaging and Philips sign MOU to strengthen imaging capabilities across Asia Pacific
New collaboration combines Philips' global imaging expertise with ASCI's clinical leadership and regional network to strengthen education and clinical excellence across the region ...
2026-05-28T    Computer/Electronics   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Aphranel® MagiCCrystal CaHA Filler Achieves EU MDR Certification as a Premium Regenerative Injectable
SHANGHAI , May 28, 2026 /PRNewswire/ -- Moyom Biotechnology announced that its premium regenerative aesthetics product, Aphranel® MagiCCrystal CaHA Filler officially achieved European Union Medical ...
2026-05-28T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Scientific forum in Singapore explores advanced PET/CT imaging
SINGAPORE , May 28, 2026 /PRNewswire/ -- Singapore General Hospital (SGH), a leading academic medical centre in Singapore, on May 21 hosted "Advancing Precision Imaging with Next Generation PET/CT," ...
2026-05-28T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals   Trade show news 
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC
NANJING, China , May 28, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the Phase II clinical study ...
2026-05-28T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Dymax Expands HLC Adhesive Portfolio with New Low Viscosity Medical Product
New Adhesive Enables Reliable Bonding in Both Light and Shadowed Areas ...
2026-05-28T    Chemical   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery
SHANGHAI , May 28, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated ...
2026-05-28T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease
SUZHOU, China and MÖLNDAL, Sweden , May 28, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together "Ribo") announce the submission of ...
2026-05-28T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery
SHANGHAI , May 28, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated ...
2026-05-28T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer
SHANGHAI and HONG KONG , May 28, 2026 /PRNewswire/ -- Antengene Corporation Limited  ( "Antengene" , SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated ...
2026-05-28T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.